Request Appointment
353 East 68th StreetNew York, NY 10065
Overview of Dr. Autio
Dr. Karen Autio is an oncologist in New York, NY and is affiliated with multiple hospitals in the area, including Memorial Sloan Kettering Cancer Center and Memorial Hospital for Cancer and allied Diseases. She received her medical degree from Stony Brook University Health Sciences Center School of Medicine and has been in practice 19 years. She is one of 526 doctors at Memorial Sloan Kettering Cancer Center and one of 91 doctors at Memorial Hospital for Cancer and allied Diseases who specialize in Oncology. She has more than 50 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2010 - 2013
University of Virginia Medical CenterResidency, Internal Medicine, 2007 - 2010
Stony Brook University Health Sciences Center School of MedicineClass of 2007
Certifications & Licensure
NJ State Medical License 2021 - 2027
NY State Medical License 2010 - 2027
CT State Medical License 2024 - 2026
VA State Medical License 2007 - 2010
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification MyMSK, Memorial Sloan Kettering, 2016-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
- CMS Meaningful Use Stage 1 Certification Sunrise Ambulatory Care, Allscripts, 2016-2017
Clinical Trials
- A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors Start of enrollment: 2013 Nov 15
- Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy Start of enrollment: 2013 Dec 18
- A Study of Olaparib and Durvalumab in Prostate Cancer Start of enrollment: 2019 Mar 07
Publications & Presentations
PubMed
- Genomic Features and Response to Poly(ADP-ribose) Polymerase Inhibition in Metastatic Castration-Resistant Prostate Cancer.Jeffery C W Chang, Subhiksha Nandakumar, Konrad H Stopsack, Christopher Fong, Karl Pichotta
JCO Precision Oncology. 2026-03-01 - Accelerating Drug Development in Hormone-Naïve Prostate Cancer through Multimodal Therapy Strategies: The MetaCURE Phase 2 Randomized Clinical Trial.Deaglan McHugh, Matthew Dallos, Min Yuen Teo, Sean M McBride, Anuradha Gopalan
Clinical Cancer Research. 2026-02-04 - 1 citationsNational Cancer Institute's Working Group on Biochemically Recurrent Prostate Cancer: Clinical Trial Design Considerations.David J Einstein, Melissa L Abel, Jeanny B Aragon-Ching, Philip M Arlen, Karen A Autio
Journal of Clinical Oncology. 2025-12-01
Lectures
- Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), o...2019 ASCO Annual Meeting - 6/1/2019
- Phase 1 study of LY3022855, a colony-stimulating factor-1 receptor (CSF-1R) inhibitor, in patients with metastatic breast cancer (MBC) or metastatic castration-resista...2019 ASCO Annual Meeting - 6/1/2019
- Preliminary results of the first-in-human, dose-finding PROCLAIM-CX-072 trial of the PD-L1 Probody therapeutic CX-072 as monotherapy in patients (pts) with advanced so...2018 ASCO Annual Meeting - Chicago, Illinois - 06/4/2018
Press Mentions
Immune Checkpoint Blockade in Prostate Cancer: It's All About the CombinationsAugust 10th, 2020- Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer ManagementMay 30th, 2024
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
